赛诺菲特药中国区总经理纪娴：再拓免疫版图，共筑2型炎症诊疗生态

Core Insights - The 8th China International Import Expo (CIIE) serves as a crucial platform for global high-quality products and advanced technologies entering the Chinese market, particularly driving innovation in the pharmaceutical and healthcare sectors [1] - Sanofi showcased its innovative product Dupixent (dupilumab), which has received recognition for its potential in treating chronic rhinosinusitis with nasal polyps and bullous pemphigoid, highlighting its breakthroughs in expanding the immune health ecosystem [1][2] - Dupixent has been approved for seven indications in China, marking significant milestones in its treatment landscape, including the recent introduction of a new indication for chronic rhinosinusitis with nasal polyps [2][7] Industry Developments - The approval of Dupixent for chronic rhinosinusitis with nasal polyps represents a critical advancement in addressing a condition that severely impacts patients' quality of life, with high recurrence rates post-surgery [2][3] - The drug is the first biologic approved for both adults and adolescents with this condition, targeting the core mechanism of type 2 inflammation [3] - The incidence of chronic rhinosinusitis with nasal polyps has been rising over the past 25 years, with a significant portion of patients also suffering from comorbidities like asthma and allergic rhinitis [3][8] Market Impact - Dupixent's rapid approval and integration into the Chinese healthcare system demonstrate a "China speed" in bringing innovative treatments to market, significantly reducing patient burden [5][6] - The drug's expansion into respiratory diseases is timely, given the severe public health challenges posed by chronic respiratory conditions in China, including a high prevalence of COPD and asthma [5][6] - The introduction of a new pre-filled injection pen for Dupixent enhances patient convenience and self-management, aligning with the growing demand for accessible chronic disease treatments [6] Future Outlook - Sanofi aims to continue expanding Dupixent's indications in China, focusing on immune, rare diseases, and oncology, with a commitment to addressing the needs of patients suffering from type 2 inflammatory diseases [7][9] - The company is actively participating in initiatives to shift treatment paradigms from symptomatic management to addressing underlying causes of diseases, fostering a collaborative healthcare ecosystem [9] - The ongoing rise in the incidence of type 2 inflammatory diseases necessitates innovative solutions, with Dupixent positioned as a key player in this therapeutic landscape [8][9]